Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

103.06 -0.34 (-0.33%)
Official Closing Price Updated: 7:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
42 43 Next >
Biogen Posts New Updates Across its Spinraza SMA Research Program
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and... 
Via Benzinga
Why Another ADHD Stimulant? Cingulate Inc. Believes It's All About The Timing
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. People diagnosed with attention... 
Via Benzinga
Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat
Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO... 
Via Benzinga
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,... 
Via Get News
NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting
The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE: NVS) Kisqali (ribociclib) plus letrozole... 
Via Benzinga
Why Are Pharming Shares Trading Higher Today?
Pharming Group NV (NASDAQ: PHAR) has annou 
Via Benzinga
Recap: Novartis Q4 Earnings
  Novartis (NYSE:NVS) reported its Q4 earnings results on Wednesday, February 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
7 Drug Stocks to Consider After the Viatris Plunge
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs
Novartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene... 
Via Benzinga
Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
Photo Credit: Photo by CDC & Klara Kulikova This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be... 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Renewable Energy Investment Market Size, Share, Trends, Industry Growth, and Forecast 2028 Top Key Players Spectrum, Roche, Pfizer, Novartis, Merck, Bayer, Healthcare Amgen
Renewable Energy Investment Market Size, Share, Growth, Industry Trends, Business Scope, Global Providers, COVID-19 Impact and Forecast 2028 
Via SBWire
Exposures COVID-19
This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors
Photo by National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing... 
Via Benzinga
Friday the 13th on the 18th
Today stock markets more or less panicked over the fear of war. 
Via Talk Markets
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Novartis Highlights Focus on Creating Value for Stakeholders and Society in New Integrated Report
SOURCE: 3BL Alerts 
Via 3BL Media
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19
Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have  
Via Benzinga
Global Diversification: Switzerland And The Philippines
One way to avoid or defend against slowing growth in the US is to own positions in other countries. There is likely a fund for almost any developed country you can think of that owns a basket of stocks... 
Via Talk Markets
A News Blizzard
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs. 
Via Talk Markets
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,... 
Via FinancialNewsMedia
Exposures COVID-19
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
Photo by Diana Polekhina on Unsplash 
Via Benzinga
Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests
Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH 
Via Benzinga
World Markets News for Wednesday
Gold and the Euro are up as the greenback loses traction. 
Via Talk Markets
Novartis Says Sandoz Future Uncertain As Generic Drug Sales Flounder
Novartis stock fell Wednesday on a disappointing fourth quarter. The company says it's still reviewing its generic drugs unit. 
Via Investor's Business Daily
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS